These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35261797)

  • 1. Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1.
    Hung YH; Lai MD; Hung WC; Chen LT
    Am J Cancer Res; 2022; 12(2):713-728. PubMed ID: 35261797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA TDRG1 promotes hypoxia-induced glycolysis by targeting the miR-214-5p/SEMA4C axis in cervical cancer cells.
    Li X; Zhang C; Tian Y
    J Mol Histol; 2021 Apr; 52(2):245-256. PubMed ID: 33394293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaphorin 4C Promotes Macrophage Recruitment and Angiogenesis in Breast Cancer.
    Yang J; Zeng Z; Qiao L; Jiang X; Ma J; Wang J; Ye S; Ma Q; Wei J; Wu M; Huang X; Ma D; Gao Q
    Mol Cancer Res; 2019 Oct; 17(10):2015-2028. PubMed ID: 31308149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.
    Smeester BA; Slipek NJ; Pomeroy EJ; Bomberger HE; Shamsan GA; Peterson JJ; Crosby MR; Draper GM; Becklin KL; Rahrmann EP; McCarthy JB; Odde DJ; Wood DK; Largaespada DA; Moriarity BS
    Oncogene; 2020 Jan; 39(5):1049-1062. PubMed ID: 31582836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C.
    Li J; Wang Q; Wen R; Liang J; Zhong X; Yang W; Su D; Tang J
    J Cell Mol Med; 2015 Dec; 19(12):2793-805. PubMed ID: 26283050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semaphorin 4C regulates ovarian steroidogenesis through RHOA/ROCK1-mediated actin cytoskeleton rearrangement.
    Chen D; Wu C; Wei S; Guo Y; Wu M; Zhou S; Fu F; Tang W; Xue L; Zhang J; Li Y; Dai J; Li Y; Ye S; Wang S
    Mol Hum Reprod; 2023 Apr; 29(5):. PubMed ID: 36892447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study.
    Wang Y; Qiao L; Yang J; Li X; Duan Y; Liu J; Chen S; Li H; Liu D; Fang T; Ma J; Li X; Ye F; Wan J; Wei J; Xu Q; Guo E; Jin P; Wu M; Zhang L; Xia Y; Wu Y; Shao J; Feng Y; Zhang Q; Yang Z; Chen G; Zhang Q; Li X; Wang S; Hu J; Wang X; Tan MP; Takabe K; Kong B; Yang Q; Ma D; Gao Q
    Cancer Commun (Lond); 2021 Dec; 41(12):1373-1386. PubMed ID: 34738326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semaphorin 4C: A Novel Component of B-Cell Polarization in Th2-Driven Immune Responses.
    Xue D; Desjardins M; Kaufman GN; Béland M; Al-Tamemi S; Ahmed E; Tao S; Friedel RH; Mourad W; Mazer BD
    Front Immunol; 2016; 7():558. PubMed ID: 28003812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaphorin-4C is upregulated in epithelial ovarian cancer.
    Huang S; Han S; Zhang J; Zhong Z; Wang J
    Oncol Lett; 2020 Apr; 19(4):3333-3338. PubMed ID: 32256827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High SEMA4C expression promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal carcinoma.
    Hou Y; Wang W; Zeng Z; Gan W; Lv S; Li T; Yan Z; Zhang R; Yang M
    Aging (Albany NY); 2020 Nov; 12(21):21992-22018. PubMed ID: 33177246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sema4C modulates the migration of primary tumor-associated lymphatic endothelial cells via an ERK-mediated pathway.
    Peng J; Liu X; Li C; Gao M; Wang H
    Exp Ther Med; 2021 Oct; 22(4):1102. PubMed ID: 34504556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erbin interacts with Sema4C and inhibits Sema4C-induced epithelial-mesenchymal transition in HK2 cells.
    Zhou QD; Ning Y; Zeng R; Chen L; Kou P; Xu CO; Pei GC; Han M; Xu G
    J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):672-679. PubMed ID: 24142719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential.
    Gurrapu S; Pupo E; Franzolin G; Lanzetti L; Tamagnone L
    Cell Death Differ; 2018 Jul; 25(7):1259-1275. PubMed ID: 29555978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaphorin 4C Protects against Allergic Inflammation: Requirement of Regulatory CD138+ Plasma Cells.
    Xue D; Kaufman GN; Dembele M; Beland M; Massoud AH; Mindt BC; Fiter R; Fixman ED; Martin JG; Friedel RH; Divangahi M; Fritz JH; Mazer BD
    J Immunol; 2017 Jan; 198(1):71-81. PubMed ID: 27881703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C.
    Wei JC; Yang J; Liu D; Wu MF; Qiao L; Wang JN; Ma QF; Zeng Z; Ye SM; Guo ES; Jiang XF; You LY; Chen Y; Zhou L; Huang XY; Zhu T; Meng L; Zhou JF; Feng ZH; Ma D; Gao QL
    Clin Cancer Res; 2017 Jan; 23(1):214-224. PubMed ID: 27401250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of SEMA4C Inhibit Epithelial-Mesenchymal Transition (EMT) and the Invasion and Metastasis of Cervical Cancer Cells via Inhibiting Transforming Growth Factor-beta 1 (TGF-β1)-Induced Hela cells p38 Mitogen-Activated Protein Kinase (MAPK) Activation.
    Yang L; Yu Y; Xiong Z; Chen H; Tan B; Hu H
    Med Sci Monit; 2020 Jan; 26():e918123. PubMed ID: 31951596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of microrna-138 on epithelial-Mesenchymal transition and invasion of breast cancer cells by targeting semaphorin 4C.
    Liu H; Ye H; Li X
    Bioengineered; 2021 Dec; 12(2):10117-10125. PubMed ID: 34747314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverse signaling by semaphorin 4C elicits SMAD1/5- and ID1/3-dependent invasive reprogramming in cancer cells.
    Gurrapu S; Franzolin G; Fard D; Accardo M; Medico E; Sarotto I; Sapino A; Isella C; Tamagnone L
    Sci Signal; 2019 Aug; 12(595):. PubMed ID: 31431542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 20. Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cells.
    Jing L; Bo W; Yourong F; Tian W; Shixuan W; Mingfu W
    Sci Rep; 2019 Nov; 9(1):17727. PubMed ID: 31776419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.